Logo (WIPO, 12.12.2017)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke wurde als Bildmarke am 12.12.2017 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Segmente oder Sektoren von Kreisen oder Ellipsen #Halbkreise, Halbellipsen
| Markenform | Bildmarke |
| Aktenzeichen | 1391678 |
| Länder | 
|
| Basismarke |
Nr. ,
01. Juli 2024
|
| Anmeldedatum | 12. Dezember 2017 |
| Ablaufdatum | 12. Dezember 2027 |
Markeninhaber
151 Oyster Point Blvd,
Suite 400
US
Suite 400
US
Markenvertreter
Sughrue Mion, PLLC,
2000 Pennsylvania Ave. NW.
US
Waren und Dienstleistungen
01
Biochemicals for scientific, laboratory, and research use,
namely, proteolytically-activatable, protease-activatable,
or proteolytically activated or protease-activated
immunoglobulin and antigen-binding fragments for binding to
tissue, cells and antigens; diagnostic kits for scientific,
laboratory, and research use comprising
proteolytically-activatable or protease-activatable,
proteolytically-activated or protease-activated
immunoglobulin and antigen-binding fragments for binding to
tissue, cells, and antigens; immunoglobulin and
antigen-binding fragments for drug conjugation and targeted
cell binding for laboratory and research use; assays and
reagents for use in scientific, laboratory and research
purposes; biochemical test kits comprising assays and
reagents for scientific, laboratory and research purposes;
assay kits comprising assays and reagents for measuring,
monitoring, testing and analyzing proteolytic activation and
antibody binding for scientific, laboratory and research
use
05
Biological drugs for use in treating cancer, infections,
autoimmunity, and inflammation; therapeutic and medical
diagnostic agents and preparations for use in therapies and
diagnosis for cancer, infections, autoimmunity, and
inflammation; biochemicals, immunoglobulins and
antigen-binding fragments for use in therapies and medical
diagnosis for cancer, infections, autoimmunity, and
inflammation; engineered cell therapies for medical
purposes, namely, for use in treating cancer, infections,
autoimmunity, and inflammation; therapeutic and diagnostic
agents, preparations and substances for medical purposes for
targeting application to immune system, cells, or genes;
immune modulators, immunoglobulin drug conjugates,
immunotherapies and therapeutic and diagnostic agents,
preparations and substances in the field of dysregulated
proteolytic activity for medical purposes; immunotherapies
and therapeutic and medical diagnostic agents, preparations
and substances in the field of cancer, infections,
autoimmunity, and inflammation for medical purposes; assays
and reagents for use in medical, medical diagnostic and
therapeutic purposes for proteolytic activation and binding
to tumor cells; biochemical test kits comprised of assays
and reagents for medical, medical diagnostic and therapeutic
purposes for proteolytic activation and binding to tumor
cells; assay kits comprised of assays and reagents for
measuring, monitoring, testing and analyzing proteolytic
activation, antibody binding, therapeutic treatments and
patient recovery for medical, medical diagnostic and
therapeutic purposes; assay kits comprised of assays and
reagents for use in identifying candidate patient
populations for specific therapeutic treatments for medical
purposes; therapeutic kits comprising
proteolytically-activatable or protease-activatable,
proteolytically-activated or protease-activated
immunoglobulin and antigen-binding fragments for binding to
tissue, cells, and antigens
42
Scientific research and development in the field of
therapeutic biochemicals, engineered cell therapies and
immunotherapy, oncology and dysregulated proteolytic
activity; medical and scientific research and development
for agents, preparations, products and technology in the
field of dysregulated proteolytic activities; providing
medical and scientific research information in the fields of
biochemicals, engineered cell therapies, immunotherapy,
oncology and dysregulated proteolytic activity; scientific
investigations for medical purposes; medical research;
providing scientific and medical research information and
analysis relating to biochemicals, engineered cell therapies
and immunotherapy; proteolytic activation, antibody binding,
therapeutic treatments, patient recovery, and the
identification of candidate patients for specific
therapeutic treatments; testing, research, design and
development services in the field of biochemicals for
scientific and medical research purposes; research, design
and development of assays for measuring, monitoring, testing
and analyzing proteolytic activation, antibody binding,
therapeutic treatments and patient recovery, and for
identifying candidate patient populations for specific
therapeutic treatments; providing technical support and
consultation services relating to antibody selection and
use, namely, providing technical scientific research
consultation services; online computer services in the
nature of providing a search engine for obtaining data,
namely, searching, retrieving, and providing information on
antibodies and research topics pertaining to antibodies on a
global computer network
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 07. Dezember 2021 | 2022/1 Gaz | US | RAW: Partial Ceasing Effect |
| 01. Oktober 2019 | 2020/19 Gaz | MX | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 20. Juni 2019 | 2019/26 Gaz | KR | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 30. April 2019 | 2019/18 Gaz | NZ | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 14. März 2019 | 2019/12 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 05. Februar 2019 | 2019/7 Gaz | IL | Ablehnung |
| 07. Dezember 2018 | 2018/50 Gaz | CN | Ablehnung |
| 29. November 2018 | 2019/8 Gaz | SG | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 15. November 2018 | 2018/47 Gaz | MX | Ablehnung |
| 25. Oktober 2018 | 2018/43 Gaz | JP | Ablehnung |
| 19. Oktober 2018 | 2018/43 Gaz | KR | Ablehnung |
| 18. Oktober 2018 | 2018/43 Gaz | RU | Ablehnung |
| 01. Oktober 2018 | 2018/40 Gaz | IN | Ablehnung |
| 27. September 2018 | 2018/39 Gaz | AU | Ablehnung |
| 18. September 2018 | 2018/44 Gaz | US | RAW: Division or Merger of Basic Registration |
| 02. Juni 2018 | 2018/24 Gaz | SG | Ablehnung |
| 22. März 2018 | 2018/13 Gaz | NZ | Ablehnung |
| 12. Dezember 2017 | 2018/7 Gaz | US | Eintragung |
ID: 141391678